Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing

View original at nasdaq.com
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing Key Points Whitehead sold 3,901 shares for a total transaction value of approximately ~$828K on June 3, 2026…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AMR's operating margin has slipped to -2.0% after peaking at nearly 50% in 2022.

    60% confidence
  • AMR stock trades at a P/S ratio of 1.2x, above AMR's lifetime average P/S of 0.6x, indicating it is trading at a relative premium.

    60% confidence
  • Motley Fool Stock Advisor has a total average return of 941%, outperforming the S&P 500's 206% return.

    60% confidence
  • AMR is likely fairly priced at current levels given the oversupplied metallurgical coal market and current valuation.

    60% confidence
  • AMR stock is essentially flat year-to-date as the metallurgical coal market has cooled following several years of tight supply and high demand, and AMR's profit margins have suffered.

    60% confidence
  • Whitehead's average sell-only trade size over the past four events is approximately 18,451 shares; the smaller June 3 sale is explained by reduced remaining share capacity after prior sales.

    60% confidence
  • Whitehead's prior two open-market sales since January 25, 2025 reflect declining sale sizes as available holdings decrease, with the June 3 sale being the smallest disposition in the last four sell transactions.

    60% confidence
  • Alpha Metallurgical Resources was not identified as one of the 10 best stocks for investors to buy now by the Motley Fool Stock Advisor analyst team.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing — Source | Via News | ViaNews Market